A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite …

P Emery, J Vencovský, A Sylwestrzak… - Annals of the …, 2017 - ard.bmj.com
Objectives To compare the efficacy and safety of SB4 (an etanercept biosimilar) with
reference product etanercept (ETN) in patients with moderate to severe rheumatoid arthritis …

[HTML][HTML] Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

P Emery, J Vencovský, A Sylwestrzak… - Annals of the …, 2017 - ard.bmj.com
Objectives SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a
randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and …

[PDF][PDF] Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: A randomized, Double‐Blind, phase II trial

S Cohen, K Tuckwell, TR Katsumoto… - Arthritis & …, 2020 - Wiley Online Library
Objective To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of
Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA). Methods …

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

P Emery, J Vencovský, A Sylwestrzak… - …, 2017 - academic.oup.com
Objective To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with
reference etanercept (ETN) in patients with active RA. Methods In a phase 3, randomized …

FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients …

J Vencovský, A Sylwestrzak, P Leszczyński… - 2015 - ard.bmj.com
Background SB4 is a biologic agent developed as a biosimilar of the etanercept reference
product (ETN). Etanercept is approved for treatment of rheumatoid arthritis (RA), juvenile …

[CITATION][C] Additional Efficacy Results of SB4 (Etanercept Biosimilar) up to Week 100: Comparison Between Continuing SB4 and Switching from Reference …

P Emery, J Vencovsky… - ARTHRITIS & …, 2016 - … ST, HOBOKEN 07030-5774, NJ USA

[CITATION][C] Comparison between continuing SB4 (etanercept biosimilar) and switching from reference etanercept to SB4: long-term safety and efficacy of SB4 from a …

P Emery, J Vencovsky… - Journal of …, 2017 - … PUBL CO 365 BLOOR ST E, STE …